A phase 2 study of alpha interferon for molecularly measurable residual disease in chronic myeloid leukemia after allogeneic hematopoietic cell transplantation. [electronic resource]
Producer: 20200828Description: 2754-2761 p. digitalISSN:- 1029-2403
- Adolescent
- Adult
- Aged
- Antiviral Agents -- therapeutic use
- Female
- Follow-Up Studies
- Hematopoietic Stem Cell Transplantation -- adverse effects
- Humans
- Interferon-alpha -- therapeutic use
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive -- pathology
- Male
- Middle Aged
- Neoplasm Recurrence, Local -- drug therapy
- Neoplasm, Residual -- drug therapy
- Prognosis
- Retrospective Studies
- Survival Rate
- Transplantation, Homologous
- Young Adult
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.